Search

Your search keyword '"Katsanos, Konstantinos H."' showing total 666 results
Start Over Author "Katsanos, Konstantinos H."
666 results on '"Katsanos, Konstantinos H."'

2. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission

Author

Burisch, Johan, Zhao, Mirabella, Odes, Selwyn, De Cruz, Peter, Vermeire, Severine, Bernstein, Charles N, Kaplan, Gilaad G, Duricova, Dana, Greenberg, Dan, Melberg, Hans O, Watanabe, Mamoru, Ahn, Hyeong Sik, Targownik, Laura, Pittet, Valérie E H, Annese, Vito, Park, KT, Katsanos, Konstantinos H, Høivik, Marte L, Krznaric, Zeljko, Chaparro, María, Loftus, Edward V, Jr, Lakatos, Peter L, Gisbert, Javier P, Bemelman, Willem, Moum, Bjorn, Gearry, Richard B, Kappelman, Michael D, Hart, Ailsa, Pierik, Marieke J, Andrews, Jane M, Ng, Siew C, D'Inca, Renata, and Munkholm, Pia

Published
2023
Full Text
View/download PDF

3. Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled Trial

Author

Ben-Horin, Shomron, Har-Noy, Ofir, Katsanos, Konstantinos H., Roblin, Xavier, Chen, Minhu, Gao, Xiang, Schwartz, Doron, Cheon, Jae Hee, Cesarini, Monica, Bojic, Daniela, Protic, Marijana, Theodoropoulou, Angeliki, Abu-Kaf, Heba, Engel, Tal, Tang, Jian, Veyrard, Pauline, Lin, Xiaoqing, Mao, Ren, Christodoulou, Dimitrios, Karmiris, Konstantinos, and Knezevic-Ivanovski, Tamara

Published
2022
Full Text
View/download PDF

4. Exploring Chemoprevention in Colorectal Cancer for Patients with Inflammatory Bowel Disease: Mechanisms of Action and Clinical Aspects.

Author

Fousekis, Fotios S., Mpakogiannis, Konstantinos, Filis, Panagiotis, Skamnelos, Alexandros, Christodoulou, Dimitrios K., Mauri, Davide, and Katsanos, Konstantinos H.

Subjects
COLITIS prevention, INFLAMMATORY bowel disease treatment, CHEMOPREVENTION, MESALAMINE, ANTI-inflammatory agents, CROHN'S disease, EARLY detection of cancer, BILE acids, ASPIRIN, FOLIC acid, COLORECTAL cancer, FUNCTIONAL foods, OXIDATIVE stress, BIOLOGICAL products, ULCERATIVE colitis, INFLAMMATORY bowel diseases, PURINES, STATINS (Cardiovascular agents), ADALIMUMAB, DRUG efficacy, INDIVIDUALIZED medicine, CARCINOGENESIS, INFLIXIMAB, PREVENTIVE health services, COLONOSCOPY, DIET therapy, INTERLEUKINS, PHARMACODYNAMICS, DISEASE complications, CHEMICAL inhibitors
Abstract

Simple Summary: Patients with inflammatory bowel diseases (IBD) are at an increased risk of colorectal cancer (CRC) due to the chronic inflammation in the colon. This review examines potential strategies to prevent CRC in these patients, focusing on medications such as mesalazine, thiopurines, anti-TNF agents, and statins, as well as nutraceuticals and dietary interventions. These approaches aim to address inflammation and other mechanisms related to cancer in order to reduce CRC risk. Although many treatments show promise, further studies are needed to refine dosages, assess long-term safety, and investigate the combined use of different therapies. Regular colonoscopy and personalized prevention strategies are essential for lowering cancer risk and improving outcomes. Background: Inflammatory bowel diseases (IBDs) have been associated with a higher risk of colorectal cancer (CRC) development and chronic colonic inflammation seems to have a critical role in the pathogenesis of CRC in patients suffering from IBD. In respect to that, surveillance colonoscopy at regular intervals is recommended in patients with colitis. Objective: This review aims to explore the chemopreventive potential of a range of agents, including mesalazine, thiopurines, anti-TNF agents, statins, ursodeoxycholic acid, aspirin, folic acid, and nutraceuticals. Results: These agents target inflammation, oxidative stress, and oncogenic pathways, thereby offering the potential to reduce the risk of CRC in patients with IBD. Anti-TNF agents, such as infliximab and adalimumab, not only reduce colonic inflammation, but also play a protective role against CRC by lessening the carcinogenic effects associated with prolonged inflammatory processes. Furthermore, mesalazine and thiopurines have demonstrated established efficacy, while newer biologics, including interleukin inhibitors, show promising advancements. Although nutraceuticals and dietary interventions require further clinical validation, they offer additional possibilities for non-pharmacological prevention. Conclusion: Despite progress, knowledge gaps persist regarding the long-term safety, optimal dosing, and combined use of these agents. A significant reduction in the incidence of CRC in patients with IBD could be achieved by advancing chemoprevention and personalizing strategies. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

5. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study

Author

Turk, Niksa, Cukovic-Cavka, Silvija, Nicolaou, Anastasia, Lukas, Milan, Shonová, Olga, Blichfeldt, Birgitte, Marker, Dorte, Carlsen, Katrine, Weimers, Petra, Aalykke, Clays, Kudsk, Karen, Vind, Ida, Thorsgaard, Niels, Skamnelos, Alexandros, Politis, Dimitrios, Vegh, Zsuzsanna, Demenyi, Peterne, Nemethne Kramli, Szabina, Dal Piaz, Giualia, Santini, Alessia, Girardin, Giulia, Kupcinskas, Limas, Jonaitis, Laimas, Valantiene, Irena, Zykus, Romanas, Kucinskiene, Ruta, Lazar, Daniela, Nikulina, Inna, de Castro, Luisa, Pineda, Juan-Ramon, Pereira, Santos, Martinez-Cadilla, Jesus, Sanroman, Luciano, Figueira, Montserrat, Ares, David Martinez, Rodriguez-Prada, Jose-Ignacio, Carmona, Amalia, Gonzalez-Portela, Carlos, Widen, Ulla-Britt, Myers, Sally, Ashton, Katherine, Whitehead, Emma, Burisch, Johan, Vardi, Hillel, Schwartz, Doron, Friger, Michael, Kiudelis, Gediminas, Kupčinskas, Juozas, Fumery, Mathurin, Gower-Rousseau, Corinne, Lakatos, Laszlo, Lakatos, Peter L, D'Incà, Renata, Sartini, Alessandro, Valpiani, Daniela, Giannotta, Martina, Arebi, Naila, Duricova, Dana, Bortlik, Martin, Chetcuti Zammit, Stefania, Ellul, Pierre, Pedersen, Natalia, Kjeldsen, Jens, Midjord, Jóngerð Maria Miné, Nielsen, Kári Rubek, Winther Andersen, Karina, Andersen, Vibeke, Katsanos, Konstantinos H, Christodoulou, Dimitrios K, Domislovic, Viktor, Krznaric, Zeljko, Sebastian, Shaji, Oksanen, Pia, Collin, Pekka, Barros, Luisa, Magro, Fernando, Salupere, Riina, Kievit, Hendrika Adriana Linda, Goldis, Adrian, Kaimakliotis, Ioannis P, Dahlerup, Jens F, Eriksson, Carl, Halfvarson, Jonas, Fernandez, Alberto, Hernandez, Vicent, Turcan, Svetlana, Belousova, Elena, Langholz, Ebbe, Munkholm, Pia, and Odes, Selwyn

Published
2020
Full Text
View/download PDF

9. Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Greece

Author

Gatopoulou, Anthia, Christodoulou, Dimitrios K., Katsanos, Konstantinos H., Bakos, Dimitrios, Mouzas, Ioannis, Tzouvala, Maria, Theodoropoulou, Angeliki, Paspatis, Gregorios, Theocharis, George, Thomopoulos, Konstantinos, Giouleme, Olga, Kourikou, Anastasia, Manolakopoulos, Spilios, Zampeli, Evanthia, Michopoulos, Spyros, Karatzas, Pantelis, Katsaros, Marios, Moschovis, Dimitris, Orfanoudaki, Eleni, Livieratos, Achilleas, Petrikkou, Evangelia, and Mantzaris, Gerassimos J.

Published
2021
Full Text
View/download PDF

12. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis

Author

Demolin, Julie, Détré, Patricia, Brillaut, Gaëlle, Carbonnel, Franck, Colombel, Jean Frédéric, Filippi, Jérome, Katsanos, Konstantinos H., Peyrin-Biroulet, Laurent, Allez, Mathieu, Nachury, Maria, Novacek, Gottfried, Danese, Silvio, Abitbol, Vered, Bossa, Fabrizio, Moreau, Jacques, Bommelaer, Gilles, Bourreille, Arnaud, Fumery, Mathurin, Roblin, Xavier, Reinisch, Walter, Bouhnik, Yoram, Brixi, Hedia, Seksik, Philippe, Malamut, Georgia, Färkkilä, Martti, Coulibaly, Baya, Dewit, Olivier, Louis, Edouard, Deplanque, Dominique, Michetti, Pierre, Sarter, Hélène, and Laharie, David

Published
2016
Full Text
View/download PDF

13. Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study

Author

Chetcuti Zammit, Stefania, Ellul, Pierre, Girardin, Giulia, Valpiani, Daniela, Nielsen, Kári R., Olsen, Jóngerð, Goldis, Adrian, Lazar, Daniela, Shonová, Olga, Nováková, Marie, Sebastian, Shaji, Whitehead, Emma, Carmona, Amalia, Martinez-Cadilla, Jesus, Dahlerup, Jens F., Kievit, Adriana L.H., Thorsgaard, Niels, Katsanos, Konstantinos H., Christodoulou, Dimitrios K., Magro, Fernando, Salupere, Riina, Pedersen, Natalia, Kjeldsen, Jens, Carlsen, Katrine, Ioannis, Kaimaklioti, Bergemalm, Daniel, Halfvarson, Jonas, Duricova, Dana, Bortlik, Martin, Collin, Pekka, Oksanen, Pia, Kiudelis, Gediminas, Kupcinskas, Limas, Kudsk, Karen, Andersen, Vibeke, O’Morain, Colm, Bailey, Yvonne, Doron, Schwartz, Shmuel, Odes, Almer, Sven, Arebi, Naila, Misra, Ravi, Čuković-Čavka, Silvija, Brinar, Marko, Munkholm, Pia, Vegh, Zsuzsanna, and Burisch, Johan

Published
2018
Full Text
View/download PDF

14. Comparison between tofacitinib and ustekinumab as a third‐line therapy in refractory ulcerative colitis: A multicenter international study

Author

Allocca, Mariangela, Catalano, Gaia, Savarino, Edoardo V., Chaparro, María, Levartovsky, Asaf, Michalopoulos, George, Viazis, Nikos, Fousekis, Fotis S., Psistakis, Andreas, Noviello, Daniele, Nascimento, Catarina Neto do, Caron, Benedicte, Kitsou, Vassiliki, Bamias, Giorgos, García, María José, Zacharopoulou, Eirini, Foteinogiannopoulou, Kalliopi, D'Amico, Ferdinando, Koutroubakis, Ioannis, Ellul, Pierre, Tzouvala, Maria, Peyrin‐Biroulet, Laurent, Torres, Joana, Caprioli, Flavio, Karmiris, Konstantinos, Theodoropoulou, Angeliki, Katsanos, Konstantinos H., Christodoulou, Dimitrios K., Mantzaris, Gerassimos J., Kopylov, Uri, Gisbert, Javier P., Danese, Silvio, Magro, Fernando, Carla, Fornari, and Fiorino, Gionata

Abstract

Ustekinumab and tofacitinib have recently been approved for the management of moderate to severe ulcerative colitis (UC). However, there is no evidence on how they should be positioned in the therapeutic algorithm. The aim of this study was to compare tofacitinib and ustekinumab as third‐line therapies in UC patients in whom anti‐TNF and vedolizumab had failed. This was a multicenter retrospective observational study. The primary outcome was disease progression, defined as the need for steroids, therapy escalation, UC‐related hospitalization and/or surgery. Secondary outcomes were clinical remission, normalization of C‐reactive protein, endoscopic remission, treatment withdrawal, and adverse events. One‐hundred seventeen UC patients were included in the study and followed for a median time of 11.6 months (q1–q3,5.5–18.7). Overall, 65% of patients were treated with tofacitinib and 35% with ustekinumab. In the entire study cohort, 63 patients (54%) had disease progression during the follow‐up period. Treatment with ustekinumab predicted increased risk of disease progression compared to treatment with tofacitinib in Cox regression analysis (HR: 1.93 [95% CI: 1.06–3.50] p= 0.030). Twenty‐eight (68%) patients in the ustekinumab group and 35 (46%) in the tofacitinib group had disease progression over the follow‐up period (log‐rank test, p< 0.054). No significant differences were observed for the secondary outcomes. Six and 22 adverse events occurred in the ustekinumab and tofacitinib groups, respectively (15% vs. 31%, p= 0.11). Tofacitinib was more efficacious in reducing disease progression than ustekinumab in this cohort of refractory UC patients. However, prospective head‐to‐head clinical trials are needed as to confirm these data.

Published
2024
Full Text
View/download PDF

16. The cost of inflammatory bowel disease in high-income settings:a Lancet Gastroenterology & Hepatology Commission

Author

Burisch, Johan, Zhao, Mirabella, Odes, Selwyn, De Cruz, Peter, Vermeire, Severine, Bernstein, Charles N., Kaplan, Gilaad G., Duricova, Dana, Greenberg, Dan, Melberg, Hans O., Watanabe, Mamoru, Ahn, Hyeong Sik, Targownik, Laura, Pittet, Valérie E.H., Annese, Vito, Park, K. T., Katsanos, Konstantinos H., Høivik, Marte L., Krznaric, Zeljko, Chaparro, María, Loftus, Edward V., Lakatos, Peter L., Gisbert, Javier P., Bemelman, Willem, Moum, Bjorn, Gearry, Richard B., Kappelman, Michael D., Hart, Ailsa, Pierik, Marieke J., Andrews, Jane M., Ng, Siew C., D'Inca, Renata, Munkholm, Pia, Burisch, Johan, Zhao, Mirabella, Odes, Selwyn, De Cruz, Peter, Vermeire, Severine, Bernstein, Charles N., Kaplan, Gilaad G., Duricova, Dana, Greenberg, Dan, Melberg, Hans O., Watanabe, Mamoru, Ahn, Hyeong Sik, Targownik, Laura, Pittet, Valérie E.H., Annese, Vito, Park, K. T., Katsanos, Konstantinos H., Høivik, Marte L., Krznaric, Zeljko, Chaparro, María, Loftus, Edward V., Lakatos, Peter L., Gisbert, Javier P., Bemelman, Willem, Moum, Bjorn, Gearry, Richard B., Kappelman, Michael D., Hart, Ailsa, Pierik, Marieke J., Andrews, Jane M., Ng, Siew C., D'Inca, Renata, and Munkholm, Pia

Abstract

The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease and ulcerative colitis in both developed and newly industrialised countries, but also the chronic nature of the diseases, the need for long-term, often expensive treatments, the use of more intensive disease monitoring strategies, and the effect of the diseases on economic productivity. This Commission draws together a wide range of expertise to discuss the current costs of IBD care, the drivers of increasing costs, and how to deliver affordable care for IBD in the future. The key conclusions are that (1) increases in health-care costs must be evaluated against improved disease management and reductions in indirect costs, and (2) that overarching systems for data interoperability, registries, and big data approaches must be established for continuous assessment of effectiveness, costs, and the cost-effectiveness of care. International collaborations should be sought out to evaluate novel models of care (eg, value-based health care, including integrated health care, and participatory health-care models), as well as to improve the education and training of clinicians, patients, and policy makers., The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease and ulcerative colitis in both developed and newly industrialised countries, but also the chronic nature of the diseases, the need for long-term, often expensive treatments, the use of more intensive disease monitoring strategies, and the effect of the diseases on economic productivity. This Commission draws together a wide range of expertise to discuss the current costs of IBD care, the drivers of increasing costs, and how to deliver affordable care for IBD in the future. The key conclusions are that (1) increases in health-care costs must be evaluated against improved disease management and reductions in indirect costs, and (2) that overarching systems for data interoperability, registries, and big data approaches must be established for continuous assessment of effectiveness, costs, and the cost-effectiveness of care. International collaborations should be sought out to evaluate novel models of care (eg, value-based health care, including integrated health care, and participatory health-care models), as well as to improve the education and training of clinicians, patients, and policy makers.

Published
2023

17. DECIDE: Delphi Expert Consensus Statement on Inflammatory Bowel Disease Dysplasia Shared Management Decision-Making

Author

Kabir, Misha, Thomas-Gibson, Siwan, Tozer, Phil J., Warusavitarne, Janindra, Faiz, Omar, Hart, Ailsa, Allison, Lisa, Acheson, Austin G., Atici, Semra Demirli, Avery, Pearl, Brar, Mantaj, Carvello, Michele, Choy, Matthew C., Dart, Robin J., Davies, Justin, Dhar, Anjan, Din, Shahida, Hayee, BuHussain, Kandiah, Kesavan, Katsanos, Konstantinos H., Lamb, Christopher Andrew, Limdi, Jimmy K., Lovegrove, Richard E., Myrelid, Pär, Noor, Nurulamin, Papaconstantinou, Ioannis, Petrova, Dafina, Pavlidis, Polychronis, Pinkney, Thomas, Proud, David, Radford, Shellie, Rao, Rohit, Sebastian, Shaji, Segal, Jonathan P., Selinger, Christian, Spinelli, Antonino, Thomas, Kathryn, Wolthuis, Albert, Wilson, Ana, Kabir, Misha, Thomas-Gibson, Siwan, Tozer, Phil J., Warusavitarne, Janindra, Faiz, Omar, Hart, Ailsa, Allison, Lisa, Acheson, Austin G., Atici, Semra Demirli, Avery, Pearl, Brar, Mantaj, Carvello, Michele, Choy, Matthew C., Dart, Robin J., Davies, Justin, Dhar, Anjan, Din, Shahida, Hayee, BuHussain, Kandiah, Kesavan, Katsanos, Konstantinos H., Lamb, Christopher Andrew, Limdi, Jimmy K., Lovegrove, Richard E., Myrelid, Pär, Noor, Nurulamin, Papaconstantinou, Ioannis, Petrova, Dafina, Pavlidis, Polychronis, Pinkney, Thomas, Proud, David, Radford, Shellie, Rao, Rohit, Sebastian, Shaji, Segal, Jonathan P., Selinger, Christian, Spinelli, Antonino, Thomas, Kathryn, Wolthuis, Albert, and Wilson, Ana

Abstract

Background and Aims Inflammatory bowel disease colitis-associated dysplasia is managed with either enhanced surveillance and endoscopic resection or prophylactic surgery. The rate of progression to cancer after a dysplasia diagnosis remains uncertain in many cases and patients have high thresholds for accepting proctocolectomy. Individualised discussion of management options is encouraged to take place between patients and their multidisciplinary teams for best outcomes. We aimed to develop a toolkit to support a structured, multidisciplinary and shared decision-making approach to discussions about dysplasia management options between clinicians and their patients. Methods Evidence from systematic literature reviews, mixed-methods studies conducted with key stakeholders, and decision-making expert recommendations were consolidated to draft consensus statements by the DECIDE steering group. These were then subjected to an international, multidisciplinary modified electronic Delphi process until an a priori threshold of 80% agreement was achieved to establish consensus for each statement. Results In all, 31 members [15 gastroenterologists, 14 colorectal surgeons and two nurse specialists] from nine countries formed the Delphi panel. We present the 18 consensus statements generated after two iterative rounds of anonymous voting. Conclusions By consolidating evidence for best practice using literature review and key stakeholder and decision-making expert consultation, we have developed international consensus recommendations to support health care professionals counselling patients on the management of high cancer risk colitis-associated dysplasia. The final toolkit includes clinician and patient decision aids to facilitate shared decision-making.

Published
2023
Full Text
View/download PDF

18. ECCO Guidelines on Inflammatory Bowel Disease and Malignancies

Author

Gordon, Hannah, Biancone, Livia, Fiorino, Gionata, Katsanos, Konstantinos H, Kopylov, Uri, Sulais, Eman Al, Axelrad, Jordan E, Balendran, Karthiha, Burisch, Johan, de Ridder, Lissy, Derikx, Lauranne, Ellul, Pierre, Greuter, Thomas, Iacucci, Marietta, Di Jiang, Caroline, Kapizioni, Christina, Karmiris, Konstantinos, Kirchgesner, Julien, Laharie, David, Lobatón Ortega, Triana, Molnár, Tamás, Noor, Nurulamin M, Rao, Rohit, Saibeni, Simone, Scharl, Michael, Vavricka, Stephan R, Raine, Tim, Gordon, Hannah, Biancone, Livia, Fiorino, Gionata, Katsanos, Konstantinos H, Kopylov, Uri, Sulais, Eman Al, Axelrad, Jordan E, Balendran, Karthiha, Burisch, Johan, de Ridder, Lissy, Derikx, Lauranne, Ellul, Pierre, Greuter, Thomas, Iacucci, Marietta, Di Jiang, Caroline, Kapizioni, Christina, Karmiris, Konstantinos, Kirchgesner, Julien, Laharie, David, Lobatón Ortega, Triana, Molnár, Tamás, Noor, Nurulamin M, Rao, Rohit, Saibeni, Simone, Scharl, Michael, Vavricka, Stephan R, and Raine, Tim

Published
2023

19. Effectiveness and safety of darvadstrocel in patients with complex perianal fistulizing Crohn's disease: a systematic review.

Author

Fousekis, Fotios S., Mpakogiannis, Konstantinos, Lianos, Georgios D., Koukoudis, Anastasios, Christodoulou, Dimitrios K., Papaconstantinou, Ioannis, and Katsanos, Konstantinos H.

Subjects
CROHN'S disease, PATIENT safety, CLINICAL trials, THERAPEUTICS, HEALING, STEM cell transplantation
Abstract

Background Managing complex perianal fistulizing Crohn's disease (CD) remains challenging, despite current medical and surgical treatment approaches. Darvadstrocel, a therapy utilizing adipose-derived stem cells, shows promise in promoting tissue regeneration and healing, offering a novel and effective treatment for fistula management. Method A systematic literature search was conducted on PubMed and Scopus to identify studies involving patients with complex perianal fistulizing CD treated with darvadstrocel. Results In total, 2 randomized controlled trials (RCT), 5 observational studies with retrospective data collection and 2 observational studies with prospective design were included in the final review. Data from the European ADMIRE-CD RCT demonstrated that darvadstrocel is superior to placebo in terms of clinical and imaging improvement over both the short and long term. These findings align with the prospective studies analyzed in this systematic review. The rate of treatmentemergent adverse events in the ADMIRE-CD trial's RCTs was similar in both the darvadstrocel and control groups, with perianal abscess being the most common adverse event up to 52 weeks after drug administration. Retrospective studies indicated no side-effects beyond 52 weeks. Conclusions Darvadstrocel appears to be a new, potentially effective and safe treatment option for the management of complex perianal fistulas. However, more randomized clinical trials are needed to evaluate the efficacy and safety profile of the drug. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. DECIDE: Delphi Expert Consensus Statement on Inflammatory Bowel Disease Dysplasia Shared Management Decision-Making

Author

Kabir, Misha, primary, Thomas-Gibson, Siwan, additional, Tozer, Phil J, additional, Warusavitarne, Janindra, additional, Faiz, Omar, additional, Hart, Ailsa, additional, Allison, Lisa, additional, Acheson, Austin G, additional, Atici, Semra Demirli, additional, Avery, Pearl, additional, Brar, Mantaj, additional, Carvello, Michele, additional, Choy, Matthew C, additional, Dart, Robin J, additional, Davies, Justin, additional, Dhar, Anjan, additional, Din, Shahida, additional, Hayee, Bu'Hussain, additional, Kandiah, Kesavan, additional, Katsanos, Konstantinos H, additional, Lamb, Christopher Andrew, additional, Limdi, Jimmy K, additional, Lovegrove, Richard E, additional, Myrelid, Pär, additional, Noor, Nurulamin, additional, Papaconstantinou, Ioannis, additional, Petrova, Dafina, additional, Pavlidis, Polychronis, additional, Pinkney, Thomas, additional, Proud, David, additional, Radford, Shellie, additional, Rao, Rohit, additional, Sebastian, Shaji, additional, Segal, Jonathan P, additional, Selinger, Christian, additional, Spinelli, Antonino, additional, Thomas, Kathryn, additional, Wolthuis, Albert, additional, and Wilson, Ana, additional

Published
2023
Full Text
View/download PDF

22. The Inflammatory Bowel Disease—Disk Tool for Assessing Disability in Inflammatory Bowel Disease Patients: Validation of the Greek Version

Author

Katsoula, Anastasia, primary, Axiaris, Georgios, additional, Mpitouli, Afroditi, additional, Palatianou, Maria, additional, Christidou, Angeliki, additional, Dimitriadis, Nikolaos, additional, Nakos, Andreas, additional, Pastras, Ploutarchos, additional, Kourkoulis, Panagiotis, additional, Karatzas, Pantelis, additional, Moutzoukis, Miltiadis, additional, Zlatinoudis, Charalampos, additional, Philippidis, Athanasios, additional, Kourikou, Anastasia, additional, Kokkotis, Georgios, additional, Gklavas, Antonios, additional, Machaira, Angeliki, additional, Mantaka, Aikaterini, additional, Talimtzi, Persefoni, additional, Anagnostopoulou, Evaggelia, additional, Koutroubakis, Ioannis E., additional, Papaconstantinou, Ioannis, additional, Bamias, Georgios, additional, Manolakopoulos, Spilios, additional, Mathou, Nicoletta, additional, Paraskeva, Konstantina, additional, Protopappas, Andreas, additional, Tsironi, Eftychia, additional, Katsanos, Konstantinos H., additional, Christodoulou, Dimitrios K., additional, Papatheodoridis, Georgios, additional, Michalopoulos, Georgios, additional, Theocharis, Georgios, additional, Triantos, Christos, additional, Pachiadakis, Ioannis, additional, Soufleris, Konstantinos, additional, Viazis, Nikolaos, additional, Mantzaris, Gerassimos J., additional, Tribonias, Georgios, additional, Tzouvala, Maria, additional, Theodoropoulou, Angeliki, additional, Karmiris, Konstantinos, additional, Zampeli, Evanthia, additional, Michopoulos, Spyridon, additional, Haidich, Anna-Bettina, additional, and Giouleme, Olga, additional

Published
2023
Full Text
View/download PDF

30. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis—An Evidence-based Consensus Guideline From the European Crohnʼs and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition

Author

Turner, Dan, Ruemmele, Frank M., Orlanski-Meyer, Esther, Griffiths, Anne M., de Carpi, Javier Martin, Bronsky, Jiri, Veres, Gabor, Aloi, Marina, Strisciuglio, Caterina, Braegger, Christian P., Assa, Amit, Romano, Claudio, Hussey, Séamus, Stanton, Michael, Pakarinen, Mikko, de Ridder, Lissy, Katsanos, Konstantinos H., Croft, Nick, Navas-López, Víctor Manuel, Wilson, David C., Lawrence, Sally, and Russell, Richard K.

Published
2018
Full Text
View/download PDF

35. ECCO Guidelines on Inflammatory Bowel Disease and Malignancies

Author

Gordon, Hannah, Biancone, Livia, Fiorino, Gionata, Katsanos, Konstantinos H, Kopylov, Uri, Sulais, Eman Al, Axelrad, Jordan E, Balendran, Karthiha, Burisch, Johan, de Ridder, Lissy, Derikx, Lauranne, Ellul, Pierre, Greuter, Thomas, Iacucci, Marietta, Di Jiang, Caroline, Kapizioni, Christina, Karmiris, Konstantinos, Kirchgesner, Julien, Laharie, David, Lobatón Ortega, Triana, Molnár, Tamás, Noor, Nurulamin M, Rao, Rohit, Saibeni, Simone, Scharl, Michael, Vavricka, Stephan R, Raine, Tim, University of Zurich, and Pediatrics

Subjects
10219 Clinic for Gastroenterology and Hepatology, All institutes and research themes of the Radboud University Medical Center, Gastroenterology, 610 Medicine & health, General Medicine, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
Abstract

Item does not contain fulltext

Published
2022
Full Text
View/download PDF

45. The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease

Author

Fousekis, Fotios S. Papamichael, Konstantinos Kourtis, Georgios and Albani, Eleni N. Orfanidou, Afroditi Saridi, Maria and Katsanos, Konstantinos H. Christodoulou, Dimitrios K. and Fousekis, Fotios S. Papamichael, Konstantinos Kourtis, Georgios and Albani, Eleni N. Orfanidou, Afroditi Saridi, Maria and Katsanos, Konstantinos H. Christodoulou, Dimitrios K.

Abstract

The development of biological agents against tumor necrosis factor (TNF) has revolutionized the management of inflammatorybowel disease (IBD), frequentlyachieving induction and maintenance of remission in both ulcerative colitis and Crohn’s disease. However, a loss of response due to the development of anti-drug antibodies (ADA) is seen annually in approximately 20% of IBD patients receiving anti-TNF therapy. Current evidence suggests that the use of immunomodulators (IMM), such as thiopurines (azathioprine and 6-mercaptopurine) or methotrexate, may prevent or suppress ADA formation. In this article, we present a comprehensive review of the available literature regarding the efficacy of IMM in the prevention and suppression of ADA development to anti-TNF therapy in patients with IBD.

Published
2022

46. Cancer in inflammatory bowel disease 15 years after diagnosis in a population-based European Collaborative follow-up study

Author

Katsanos, Konstantinos H., Tatsioni, Athina, Pedersen, Natalia, Shuhaibar, Mary, Ramirez, Vicent Hernandez, Politi, Patrizia, Rombrechts, Evelien, Pierik, Marieke, Clofent, Juan, Beltrami, Marina, Bodini, Paolo, Freitas, Joao, Mouzas, Ioannis, Fornaciari, Giovanni, Moum, Bjorn, Lakatos, Peter Laszlo, Vermeire, Severine, Langholz, Ebbe, Odes, Selwyn, Morain, Colm O'., Stockbrügger, Reinhold, Munkholm, Pia, and Tsianos, Epameinondas V.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results